Symbols / GUTS $0.46 -0.20%
GUTS Chart
About
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 70.43M |
| Enterprise Value | 47.46M | Income | -122.20M | Sales | 3.00K |
| Book/sh | -0.02 | Cash/sh | 0.57 | Dividend Yield | — |
| Payout | 0.00% | Employees | 101 | IPO | — |
| P/E | — | Forward P/E | -0.67 | PEG | — |
| P/S | 23476.15 | P/B | -19.13 | P/C | — |
| EV/EBITDA | -0.49 | EV/Sales | 15819.27 | Quick Ratio | 4.16 |
| Current Ratio | 4.27 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.32 | EPS next Y | -0.69 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -51.17% |
| ROE | -5.18% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -32914.00% | Profit Margin | 0.00% | Shs Outstand | 153.37M |
| Shs Float | 116.92M | Short Float | 9.82% | Short Ratio | 1.31 |
| Short Interest | — | 52W High | 3.03 | 52W Low | 0.38 |
| Beta | 1.51 | Avg Volume | 5.65M | Volume | 1.52M |
| Target Price | $5.24 | Recom | None | Prev Close | $0.46 |
| Price | $0.46 | Change | -0.20% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.24
Mean price target
2. Current target
$0.46
Latest analyst target
3. DCF / Fair value
$-5.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.46
Low
$2.00
High
$8.00
Mean
$5.24
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-30 | down | Morgan Stanley | Overweight → Equal-Weight | $2 |
| 2025-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-11-21 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2025-09-26 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-09-15 | init | HC Wainwright & Co. | — → Buy | $9 |
| 2025-08-28 | init | Ladenburg Thalmann | — → Buy | $4 |
| 2025-08-14 | main | Canaccord Genuity | Buy → Buy | $6 |
| 2025-04-15 | init | Canaccord Genuity | — → Buy | $12 |
| 2025-02-03 | main | Morgan Stanley | Overweight → Overweight | $10 |
| 2024-02-28 | init | Evercore ISI Group | — → Outperform | — |
| 2024-02-27 | init | Morgan Stanley | — → Overweight | $18 |
- Fractyl Health sets March 24 call on 2025 results, business updates - Stock Titan ue, 17 Mar 2026 11
- Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Mon, 23 Feb 2026 08
- Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? - Stocktwits hu, 29 Jan 2026 14
- Fractyl Health Receives Nasdaq Minimum Bid Price Notice - TipRanks ue, 17 Mar 2026 21
- Fractyl Health, Inc. (GUTS) Initiates Purchase: Reasons for the Rating Increase - Bitget Mon, 16 Mar 2026 17
- Fractyl Health (GUTS) Is Down 78.0% After Positive REMAIN-1 Midpoint Data And De Novo FDA Plan - Has The Bull Case Changed? - simplywall.st Sat, 31 Jan 2026 08
- Rosalind Advisors Inc. Takes Position in Fractyl Health, Inc. $GUTS - MarketBeat Fri, 13 Mar 2026 10
- $GUTS stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 28 Jan 2026 08
- Should I buy Fractyl Health, Inc. (GUTS) - Zacks Investment Research Mon, 23 Feb 2026 08
- Fractyl Health stock falls after midpoint data on GLP-1 weight maintenance - Investing.com hu, 29 Jan 2026 08
- Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts - Seeking Alpha Mon, 02 Feb 2026 08
- Fractyl trial tests Revita to prevent weight regain after GLP-1 drugs - Stock Titan hu, 26 Feb 2026 08
- With 58% institutional ownership, Fractyl Health, Inc. (NASDAQ:GUTS) is a favorite amongst the big guns - Yahoo Finance hu, 18 Dec 2025 08
- Fractyl Health, Inc. Announces Call of Tranche A Common Stock Purchase Warrants for Cancellation and Cash Consideration - Quiver Quantitative Mon, 15 Dec 2025 08
- Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Increases By 22.6% - MarketBeat ue, 17 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10416 | 19999.0 | — | Purchase at price 1.92 per share. | RAJAGOPALAN HARITH M.D., PH.D. | Chief Executive Officer | — | 2025-12-04 00:00:00 | D |
| 1 | 17901 | 22980.0 | — | Purchase at price 1.28 per share. | ROYAN AJAY G. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-14 00:00:00 | D |
| 2 | 31000 | 40210.0 | — | Purchase at price 1.30 per share. | BARNES KELLY ANN | Director | — | 2025-03-14 00:00:00 | D |
| 3 | 16129 | 20358.0 | — | Purchase at price 1.26 per share. | BRADLEY WILLIAM C | Director | — | 2025-03-13 00:00:00 | D |
| 4 | 8550 | 9964.0 | — | Purchase at price 1.17 per share. | SCHULMAN AMY W. | Director | — | 2025-03-13 00:00:00 | D |
| 5 | 8550 | 9964.0 | — | Purchase at price 1.17 per share. | CONAWAY SAMUEL | Director | — | 2025-03-13 00:00:00 | D |
| 6 | 43818 | 82266.0 | — | Sale at price 1.81 - 1.95 per share. | CAPLAN JAY DAVID | President | — | 2025-01-31 00:00:00 | D |
| 7 | 111920 | 206003.0 | — | Sale at price 1.82 - 1.95 per share. | RAJAGOPALAN HARITH M.D., PH.D. | Chief Executive Officer | — | 2025-01-31 00:00:00 | D |
| 8 | 43818 | 74491.0 | — | Conversion of Exercise of derivative security at price 1.70 per share. | CAPLAN JAY DAVID | President | — | 2025-01-31 00:00:00 | D |
| 9 | 111920 | 190264.0 | — | Conversion of Exercise of derivative security at price 1.70 per share. | RAJAGOPALAN HARITH M.D., PH.D. | Chief Executive Officer | — | 2025-01-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -110.76M | -43.76M | -48.76M | -35.90M |
| TotalUnusualItems | 17.91M | -6.79M | -176.00K | -356.00K |
| TotalUnusualItemsExcludingGoodwill | 17.91M | -6.79M | -176.00K | -356.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -68.69M | -77.09M | -46.45M | -38.73M |
| ReconciledDepreciation | 677.00K | 286.00K | 452.00K | 676.00K |
| ReconciledCostOfRevenue | 50.00K | 77.00K | 0.00 | |
| EBITDA | -92.85M | -50.55M | -48.93M | -36.25M |
| EBIT | -93.53M | -50.84M | -49.38M | -36.93M |
| NetInterestIncome | 4.15M | 1.26M | 797.00K | -1.44M |
| InterestExpense | 1.44M | |||
| InterestIncome | 4.15M | 1.26M | 797.00K | |
| NormalizedIncome | -86.60M | -70.30M | -46.28M | -38.38M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -68.69M | -77.09M | -46.45M | -38.73M |
| TotalExpenses | 93.62M | 50.96M | 49.38M | 36.93M |
| TotalOperatingIncomeAsReported | -93.53M | -50.84M | -49.38M | -36.93M |
| DilutedAverageShares | 43.54M | 47.61M | 82.43M | 47.61M |
| BasicAverageShares | 43.54M | 47.61M | 47.61M | 47.61M |
| DilutedEPS | -1.62 | -1.98 | -1.34 | -1.12 |
| BasicEPS | -1.62 | -1.98 | -1.34 | -1.12 |
| DilutedNIAvailtoComStockholders | -70.43M | -94.27M | -63.63M | -53.22M |
| NetIncomeCommonStockholders | -70.43M | -94.27M | -63.63M | -53.22M |
| PreferredStockDividends | 1.74M | 17.18M | 17.18M | 14.49M |
| NetIncome | -68.69M | -77.09M | -46.45M | -38.73M |
| NetIncomeIncludingNoncontrollingInterests | -68.69M | -77.09M | -46.45M | -38.73M |
| NetIncomeContinuousOperations | -68.69M | -77.09M | -46.45M | -38.73M |
| PretaxIncome | -68.69M | -77.09M | -46.45M | -38.73M |
| OtherIncomeExpense | 20.69M | -27.52M | 2.13M | -365.00K |
| OtherNonOperatingIncomeExpenses | 2.78M | -20.72M | 2.31M | -9.00K |
| SpecialIncomeCharges | 0.00 | -313.00K | 0.00 | |
| OtherSpecialCharges | 313.00K | |||
| GainOnSaleOfSecurity | 17.91M | -6.79M | 137.00K | -356.00K |
| NetNonOperatingInterestIncomeExpense | 4.15M | 1.26M | 797.00K | -1.44M |
| TotalOtherFinanceCost | -797.00K | 1.44M | ||
| InterestExpenseNonOperating | 1.44M | |||
| InterestIncomeNonOperating | 4.15M | 1.26M | 797.00K | |
| OperatingIncome | -93.53M | -50.84M | -49.38M | -36.93M |
| OperatingExpense | 93.57M | 50.88M | 49.38M | 36.93M |
| ResearchAndDevelopment | 70.47M | 38.04M | 34.35M | 26.43M |
| SellingGeneralAndAdministration | 23.10M | 12.84M | 15.03M | 10.49M |
| GeneralAndAdministrativeExpense | 15.03M | 10.49M | ||
| OtherGandA | 15.03M | 10.49M | ||
| GrossProfit | 43.00K | 43.00K | 0.00 | |
| CostOfRevenue | 50.00K | 77.00K | 0.00 | |
| TotalRevenue | 93.00K | 120.00K | 0.00 | 0.00 |
| OperatingRevenue | 93.00K | 120.00K | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 48.76M | 47.90M | 47.55M | 47.55M |
| ShareIssued | 48.76M | 47.90M | 47.55M | 47.55M |
| NetDebt | 21.94M | |||
| TotalDebt | 62.50M | 86.39M | 19.48M | 17.01M |
| TangibleBookValue | 28.42M | -325.06M | -252.32M | -209.32M |
| InvestedCapital | 58.59M | -269.91M | -234.56M | -193.60M |
| WorkingCapital | 51.99M | 24.46M | 44.32M | 72.73M |
| NetTangibleAssets | 28.42M | -325.06M | -252.32M | -209.32M |
| CapitalLeaseObligations | 32.34M | 31.24M | 1.72M | 1.28M |
| CommonStockEquity | 28.42M | -325.06M | -252.32M | -209.32M |
| TotalCapitalization | 58.59M | -269.91M | -234.56M | -209.32M |
| TotalEquityGrossMinorityInterest | 28.42M | -325.06M | -252.32M | -209.32M |
| StockholdersEquity | 28.42M | -325.06M | -252.32M | -209.32M |
| RetainedEarnings | -415.31M | -346.62M | -269.52M | -223.07M |
| AdditionalPaidInCapital | 443.73M | 21.55M | 17.21M | 13.75M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 79.65M | 401.27M | 313.27M | 311.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 59.88M | 390.09M | 305.96M | 288.22M |
| OtherNonCurrentLiabilities | 998.00K | 2.00K | 11.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 287.33M | 287.33M | 287.33M |
| DerivativeProductLiabilities | 1.34M | 19.10M | 407.00K | 544.00K |
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 57.54M | 83.66M | 18.23M | 334.00K |
| LongTermCapitalLeaseObligation | 27.38M | 28.51M | 465.00K | 334.00K |
| LongTermDebt | 30.16M | 55.15M | 17.76M | |
| CurrentLiabilities | 19.77M | 11.19M | 7.31M | 23.65M |
| OtherCurrentLiabilities | 831.00K | 575.00K | 36.00K | 103.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 4.96M | 2.73M | 1.25M | 16.67M |
| CurrentCapitalLeaseObligation | 4.96M | 2.73M | 1.25M | 950.00K |
| CurrentDebt | 15.72M | |||
| OtherCurrentBorrowings | 15.72M | |||
| PayablesAndAccruedExpenses | 13.99M | 7.88M | 6.03M | 6.88M |
| CurrentAccruedExpenses | 10.75M | 7.33M | 5.04M | 5.91M |
| Payables | 3.24M | 553.00K | 980.00K | 970.00K |
| AccountsPayable | 3.24M | 553.00K | 980.00K | 970.00K |
| TotalAssets | 108.08M | 76.21M | 60.96M | 102.55M |
| TotalNonCurrentAssets | 36.31M | 40.56M | 9.33M | 6.16M |
| OtherNonCurrentAssets | 4.92M | 9.79M | 7.68M | 4.82M |
| NetPPE | 31.39M | 30.77M | 1.65M | 1.34M |
| AccumulatedDepreciation | -1.59M | -4.83M | -4.54M | -4.53M |
| GrossPPE | 32.99M | 35.60M | 6.19M | 5.87M |
| Leases | 599.00K | 3.77M | 3.47M | 3.47M |
| ConstructionInProgress | 94.00K | 77.00K | 40.00K | 40.00K |
| OtherProperties | 30.54M | 30.91M | 1.84M | 1.43M |
| MachineryFurnitureEquipment | 1.76M | 853.00K | 844.00K | 927.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 71.76M | 35.65M | 51.63M | 96.39M |
| OtherCurrentAssets | 4.23M | 2.03M | 2.36M | 915.00K |
| RestrictedCash | 0.00 | 315.00K | 0.00 | |
| Inventory | 73.00K | 73.00K | 0.00 | |
| Receivables | 0.00 | 22.00K | 0.00 | |
| AccountsReceivable | 0.00 | 22.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 67.46M | 33.21M | 49.27M | 95.47M |
| CashAndCashEquivalents | 67.46M | 33.21M | 49.27M | 95.47M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -67.29M | -43.18M | -46.30M | -33.51M |
| RepaymentOfDebt | -187.00K | -84.00K | -16.05M | -7.00K |
| IssuanceOfDebt | 0.00 | 28.43M | 20.07M | 0.00 |
| IssuanceOfCapitalStock | 103.69M | 0.00 | 0.00 | 99.85M |
| CapitalExpenditure | -1.76M | -359.00K | -56.00K | -51.00K |
| InterestPaidSupplementalData | 3.13M | 762.00K | 7.00K | 1.03M |
| EndCashPosition | 71.72M | 37.78M | 53.52M | 95.47M |
| BeginningCashPosition | 37.78M | 53.52M | 95.47M | 29.11M |
| ChangesInCash | 33.94M | -15.74M | -41.95M | 66.37M |
| FinancingCashFlow | 101.23M | 27.44M | 4.35M | 99.88M |
| CashFlowFromContinuingFinancingActivities | 101.23M | 27.44M | 4.35M | 99.88M |
| NetOtherFinancingCharges | -2.85M | -963.00K | ||
| ProceedsFromStockOptionExercised | 572.00K | 52.00K | 321.00K | 40.00K |
| NetPreferredStockIssuance | 0.00 | 99.85M | ||
| PreferredStockIssuance | 0.00 | 99.85M | ||
| NetCommonStockIssuance | 103.69M | 0.00 | ||
| CommonStockIssuance | 103.69M | 0.00 | ||
| NetIssuancePaymentsOfDebt | -187.00K | 28.35M | 4.03M | -7.00K |
| NetShortTermDebtIssuance | -16.04M | 0.00 | ||
| ShortTermDebtPayments | -16.04M | 0.00 | ||
| NetLongTermDebtIssuance | -187.00K | 28.35M | 4.03M | -7.00K |
| LongTermDebtPayments | -187.00K | -84.00K | -16.05M | -7.00K |
| LongTermDebtIssuance | 0.00 | 28.43M | 20.07M | 0.00 |
| InvestingCashFlow | -1.76M | -359.00K | -56.00K | -51.00K |
| CashFlowFromContinuingInvestingActivities | -1.76M | -359.00K | -56.00K | -51.00K |
| NetPPEPurchaseAndSale | -1.76M | -359.00K | -56.00K | -51.00K |
| PurchaseOfPPE | -1.76M | -359.00K | -56.00K | -51.00K |
| OperatingCashFlow | -65.52M | -42.82M | -46.24M | -33.46M |
| CashFlowFromContinuingOperatingActivities | -65.52M | -42.82M | -46.24M | -33.46M |
| ChangeInWorkingCapital | 9.59M | 989.00K | -1.24M | 1.71M |
| ChangeInOtherWorkingCapital | 2.33M | 74.00K | 1.12M | -2.91M |
| ChangeInOtherCurrentLiabilities | 1.10M | 563.00K | ||
| ChangeInPayablesAndAccruedExpense | 8.34M | 116.00K | -919.00K | 3.76M |
| ChangeInAccruedExpense | 5.65M | 543.00K | -929.00K | 3.10M |
| ChangeInPayable | 2.69M | -427.00K | 10.00K | 666.00K |
| ChangeInAccountPayable | 2.69M | -427.00K | 10.00K | 666.00K |
| ChangeInPrepaidAssets | -2.20M | 331.00K | -1.45M | 860.00K |
| ChangeInInventory | 0.00 | -73.00K | 0.00 | |
| ChangeInReceivables | 22.00K | -22.00K | 0.00 | |
| ChangesInAccountReceivables | 22.00K | -22.00K | 0.00 | |
| OtherNonCashItems | -3.61M | 21.90M | -2.31M | 431.00K |
| StockBasedCompensation | 14.43M | 4.30M | 3.14M | 2.09M |
| DepreciationAmortizationDepletion | 677.00K | 286.00K | 452.00K | 676.00K |
| DepreciationAndAmortization | 677.00K | 286.00K | 452.00K | 676.00K |
| Depreciation | 677.00K | 286.00K | 452.00K | 676.00K |
| OperatingGainsLosses | -17.91M | 6.79M | 177.00K | 364.00K |
| GainLossOnInvestmentSecurities | -17.91M | 6.79M | -137.00K | 356.00K |
| GainLossOnSaleOfPPE | 0.00 | 1.00K | 8.00K | |
| NetIncomeFromContinuingOperations | -68.69M | -77.09M | -46.45M | -38.73M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GUTS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|